Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aveo Pharmaceuticals Inc.

www.aveooncology.com

Latest From Aveo Pharmaceuticals Inc.

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO

In a move that will generate further useful cash for AVEO, Kyowa Kirin has reacquired global rights to non-oncology uses of tivozanib.

Business Strategies Commercial

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.

Financing Business Strategies

Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3

An August 2019 analysis of overall survival in the TIVO-3 study of Aveo’s tivozanib in advanced renal cell carcinoma is now an interim rather than a final analysis, but EU regulators may take action if a negative overall survival trend is found to be continuing.

 

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Aveo Oncology
  • GENPATH PHARMACEUTICALS INC.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aveo Pharmaceuticals Inc.
  • Senior Management
  • Michael Bailey, Pres. & CEO
    Matthew Dallas, CFO
    Michael N Needle, MD, CMO
  • Contact Info
  • Aveo Pharmaceuticals Inc.
    Phone: (617) 588-1960
    One Broadway
    14th Fl.
    Cambridge, MA 02142
    USA
UsernamePublicRestriction

Register